Skip to content
Visnia
CtrlK
EconomyAI buildoutMarket MapFundsWatchlist
Log in
Market cap
Revenue
Net income
Cash on hand
Gross margin
Net margin
EPS
P/E ratio
Search
Market mapFundsWatchlist
Visnia

CCan-Fite BioPharma Ltd.

EconomyAI buildoutMarket MapFundsWatchlist
Log in
C

Can-Fite BioPharma Ltd.

  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Similar companies
  • News
  • Insider Transactions

News

News

  • Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation
    Sep 9, 2026Can-Fite BioPharma Ltd. (CANF) Press Releases
  • Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
    Sep 8, 2026Can-Fite BioPharma Ltd. (CANF) Press Releases
  • Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
    Sep 2, 2026Can-Fite BioPharma Ltd. (CANF) Press Releases
  • Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
    Sep 2, 2026Can-Fite BioPharma Ltd. (CANF) Press Releases
  • Can-Fite: Namodenoson Enhances the Anti-Cancer Effect of Chemotherapy in Pancreatic Cancer
    Aug 17, 2026Can-Fite BioPharma Ltd. (CANF) Press Releases
  • Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates
    Aug 12, 2026Can-Fite BioPharma Ltd. (CANF) Press Releases
  • Can-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndrome
    Aug 3, 2026Can-Fite BioPharma Ltd. (CANF) Press Releases
  • Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology
    Jul 20, 2026Can-Fite BioPharma Ltd. (CANF) Press Releases
  • Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer
    Jul 14, 2026Can-Fite BioPharma Ltd. (CANF) Press Releases
  • Can-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027
    Jul 6, 2026Can-Fite BioPharma Ltd. (CANF) Press Releases
  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Burn Rate
  • Similar companies
  • News
  • Insider Transactions
$2.00Close ยท Oct 8, 2026